Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Results 1 - 20 of 222 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar hydn (< 20) Submitted: 5/16/2014 10:28:57 AM : Outperform Start Price: $48.42 BMY Score: +0.87

Solid demand for ever improving products.

Recs

0
Member Avatar Johnybe (63.41) Submitted: 5/14/2014 9:46:28 PM : Outperform Start Price: $49.15 BMY Score: +0.25

strong player in this sector

Recs

0
Member Avatar DRGRNR (< 20) Submitted: 4/15/2014 7:52:17 PM : Outperform Start Price: $48.06 BMY Score: +0.79

I've owned BMY for 30 years, always a strong performer.

Recs

0
Member Avatar bassnman45 (33.55) Submitted: 1/2/2014 9:30:25 PM : Outperform Start Price: $21.01 BMY Score: +81.60

buy, hold long term and monitor

Recs

1
Member Avatar johnclanaro (< 20) Submitted: 10/28/2013 3:54:27 PM : Outperform Start Price: $51.04 BMY Score: -10.80

recent upgrade. good pipeline.

Recs

0
Member Avatar biostrategy (< 20) Submitted: 10/24/2013 12:58:47 PM : Underperform Start Price: $48.25 BMY Score: +5.74

Paten expiry coupled with a P/E of 52 does not bode well to a mature pharma concern.

Recs

1
Member Avatar gilmomp1 (44.37) Submitted: 10/16/2013 9:38:21 PM : Outperform Start Price: $47.57 BMY Score: -6.69

I bought 100 shares of this company pre 1995 and now own 188 shares by reinvesting my dividends. Now that I'm nearing retirement that dividend looks pretty good!

Recs

1
Member Avatar nancytroi (< 20) Submitted: 10/2/2013 11:43:34 AM : Outperform Start Price: $45.69 BMY Score: -4.18

Continues finding new drugs to fight cancers

Recs

0
Member Avatar lg7691 (23.35) Submitted: 7/21/2013 1:34:10 PM : Outperform Start Price: $43.01 BMY Score: +3.24

7/21/13 44.19 drug stock

Recs

2
Member Avatar usubanas (99.53) Submitted: 5/15/2013 2:35:44 AM : Outperform Start Price: $40.71 BMY Score: +6.80

I'm buying this tomorrow because of PD-1

Recs

0
Member Avatar DonkeyJunk (42.55) Submitted: 5/5/2013 10:39:09 PM : Underperform Start Price: $38.69 BMY Score: -10.77

Stock with a PE of almost 50 in an on-average overvalued market due for a significant pullback. With a company this size, the increase in revenue would have to be astronomical to justify the price.

Recs

0
Member Avatar mfwatcher (< 20) Submitted: 2/9/2013 10:45:25 AM : Outperform Start Price: $35.23 BMY Score: +15.87

Product pipeline has it positioned to outperform its peers during the recovery period.

Recs

0
Member Avatar HP2006 (76.16) Submitted: 1/28/2013 12:57:26 AM : Outperform Start Price: $34.59 BMY Score: +17.22

pharma

Recs

0
Member Avatar jrgyardley (< 20) Submitted: 12/17/2012 6:45:49 PM : Outperform Start Price: $31.05 BMY Score: +28.33

Sector
Patent expirations

Recs

0
Member Avatar TMFHelical (98.82) Submitted: 11/13/2012 9:54:12 AM : Outperform Start Price: $30.20 BMY Score: +27.50

One of the leaders of an annual industry audit that looks at value creation in the biotech space.

http://caps.fool.com/Blogs/a-look-at-established-biotech/774287

Recs

0
Member Avatar getoffmyfoot (57.73) Submitted: 11/5/2012 11:37:46 PM : Outperform Start Price: $31.41 BMY Score: +24.84

Can dividend reinvestment factor into this pick? Love the yield.

Recs

0
Member Avatar Marlonito9 (< 20) Submitted: 11/4/2012 6:31:37 PM : Underperform Start Price: $32.17 BMY Score: -23.81

This will underperform the S&P 500 because it is too strong.

Recs

1
Member Avatar tiwright (91.55) Submitted: 10/22/2012 6:59:10 PM : Outperform Start Price: $31.83 BMY Score: +25.17

Strong company, good fundamentals, good dividend. Bet LONG on BMY.

Recs

1
Member Avatar WHOVPLLC (24.74) Submitted: 8/26/2012 9:32:41 AM : Outperform Start Price: $30.49 BMY Score: +28.86

BMY has in late-stage clinical trials an Alzheimer's Drug with great promise. One of the clinical trials failed to achieve the study's "end-point." The second clinical trial did achieve the end-point.

The failure of the first failed trial has more to say about a poor choice of "end-point" than does the safety and future promise of the drug.

BMY is a STRONG long-term BUY!!!

Recs

1
Member Avatar chris293 (83.18) Submitted: 7/3/2012 9:45:26 PM : Outperform Start Price: $32.66 BMY Score: +13.35

has brought into bio-tech with the purchase of some new bio companies that must show promise otherwise why would they buy these companies.

Featured Broker Partners


Advertisement